An interventional study of Stentrode in Neurologic Disorder, ALS and Motor Neuron Disease, sponsored by Synchron, Inc.. Terminated at 2 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Synchron, Inc. · Not applicable, Interventional, and Other
Insufficient recruitment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Motor Neuron Disease with a site in Canada — 3 open to participants now, 6 under way, none of them phase 3. Motor Neuron Disease · Canada.
Among the 17 studies in Motor Neuron Disease with a site in Canada, this one is the 11th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2026, is one of 2 with no phase, and was the 17th registered.
203 studies on the registry are indexed under Motor Neuron Disease; 61 are open to participants now.
Browse Motor Neuron Disease studies →3 of the 17 studies in Motor Neuron Disease with a site in Canada are open now. Recruiting first, the newest first:
Amylyx Pharmaceuticals Inc. · Sites in Canada, United States
Ages 18+
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18+
University of Alberta · Sites in Canada
Ages 18+ · Healthy volunteers
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 43 Motor Neuron Disease studies recruiting now, 29 (67%) set no upper age limit and 2 (5%) stop at 75 or younger; 10 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1 is below the median of 30 across 104 interventional studies indexed under Motor Neuron Disease.
Median enrollment 54 across the 11 interventional studies, 132 across the 6 observational. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 17 have an industry lead sponsor. The 10 most frequent:
Synchron, Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.
Synchron, Inc. has 3 studies filed under Motor Neuron Disease — fewer than ten, so there is no comparison to draw.
2 of the studies in Motor Neuron Disease with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07193953Sunnybrook Health Sciences CentreIntravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Disruption in Amyotrophic Lateral Sclerosis (ALS) | 2026-11-30 |
| NCT06665165Amylyx Pharmaceuticals Inc.AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis | 2027-02 |
Add all 2 to your calendar (.ics) → With an account.
Among the 17 studies in Motor Neuron Disease with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Functional Outcomes and Control Using Synchron BCI - Canada (FOCUS-CAN)
Functional Outcomes and Control Using Synchron BCI - Canada (FOCUS-CAN):
The Synchron BCI motor neuroprosthesis is an implanted brain-computer interface indicated for adults with bilateral upper-limb motor impairment, including Motor Neuron Disease. The Synchron BCI is intended to replace the function of motor neurons by detecting, translating and transmitting motor-related brain signals to restore clinically meaningful control of digital devices.
The Synchron BCI is an implanted BCI device that interfaces with the brain to enable control of digital devices in individuals with bilateral upper-limb motor impairment. The Synchron BCI is designed to record volitional motor-related neural signals from the sensorimotor cortices and translate these signals into digital motor outputs to enable control of digital devices to improve functional independence. The system includes both implantable and non-implantable components. Implantable components are the Stentrode and the Transceiver.
203 studies on the registry are indexed under Motor Neuron Disease; 61 are open to participants now.
This study's enrollment of 1 is below the median of 30 across 104 interventional studies indexed under Motor Neuron Disease.
Browse Motor Neuron Disease studies →Synchron, Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.
Compared within Motor Neuron Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Nervous System Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
EXCLUSION CRITERIA:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single Arm
Device: Stentrode
The Stentrode is an endovascular electrode array that senses electrical signals from the sensorimotor cortices.
Device-related serious adverse events resulting in death or permanently increased disability up to 90 days after implant.
Time frame: 3 Months
Device-related serious adverse events resulting in death or permanently increased disability up to 1 year after implant.
Time frame: 12 Months
Target vessel patency assessed using CT venography at 90 and 365 days after implant.
Time frame: 3 Months and 12 Months
Device migration assessed using CT venography at 90 and 365 days after implant.
Time frame: 3 Months and 12 Months
Time in days from implant to device activation.
Time frame: Number of days from device implant to device activation, up to 12 months after implant.
Stability of recorded BCI signal, using monthly measurements up to 1 year after device implant.
Time frame: 12 Months
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2026 to primary completion in Sep 2026, 6 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Dec 2026 → Sep 2026 and completion Jul 2027 → Sep 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Insufficient recruitment
Insufficient recruitment
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.